SCHEMBL6545142

SCHEMBL6545142

Clc1ccc(Oc2ccc(P(Cl)Cl)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.54
MAOB P27338 2/20 0.54
LTA4H P09960 8/20 0.40
MMP1 P03956 1/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
LMNA P02545 2/20 0.39
SCN9A Q15858 1/20 0.39
HAO1 Q9UJM8 1/20 0.38
CYP2A6 P11509 1/20 0.38
CA2 P00918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7596456 0.84 LMNA (0.53) ALDH1A1MEN1CYP1A2HPGDKMT2A
SCHEMBL2879752 0.84 LMNA (0.53) ALDH1A1MEN1CYP1A2HPGDKMT2A
SCHEMBL9242729 0.82 MAOA (0.74) MAOAMAOBLTA4HALDH1A1KDM4E
SCHEMBL457634 0.82 MAOA (0.74) MAOAMAOBLTA4HALDH1A1KDM4E
SCHEMBL6545089 0.81 LTA4H (0.57) MAOAMAOBLTA4HMEN1KMT2A
SCHEMBL30385926 0.79 MAOA (0.70) MAOAMAOBLTA4HALDH1A1KDM4E
SCHEMBL9121691 0.74 MAOA (0.64) MAOAMAOBLTA4HALDH1A1KDM4E
Formaldehyde SCHEMBL28347928 0.74 MAOA (0.64) MAOAMAOBLTA4HMMP1ALDH1A1
SCHEMBL6032229 0.72
SCHEMBL196125 0.72 LTA4H (0.67) MAOAMAOBLTA4HMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379533-A2 NOVEL CYCLO AZAPHOSPHA HYDROCARBONS Leo Pharma A/S (DK) 2004-01-14 EP disclosed
US-6605742-B2 Rheumatic diseases; antiarthritic agents; antitumor agents LEO PHARMA A/S (DK) 2003-08-12 US disclosed
US-20020177706-A1 Novel cyclo azaphospha hydrocarbons LEO PHARMA A/S (DK) 2002-11-28 US disclosed
WO-2002083696-A2 NOVEL CYCLO AZAPHOSPHA HYDROCARBONS LEO PHARMA A/S (DK) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177706-A1 Novel cyclo azaphospha hydrocarbons CMA1, MMP9, CPA1 MAOA 381/4885MAOB 784/4885LTA4H 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.